Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y4SI
|
|||
| Drug Name |
Ponesimod
|
|||
| Synonyms |
854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Approved | [1] | |
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [2] | ||
| Company |
Actelion Pharmaceuticals South San Francisco, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H25ClN2O4S
|
|||
| Canonical SMILES |
CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C
|
|||
| InChI |
1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
|
|||
| InChIKey |
LPAUOXUZGSBGDU-ULCCENQXSA-N
|
|||
| CAS Number |
CAS 854107-55-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine-1-phosphate receptor 1 (S1PR1) | Target Info | Agonist | [1] |
| KEGG Pathway | FoxO signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| S1P3 pathway | ||||
| S1P1 pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| PDGFR-beta signaling pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Lysosphingolipid and LPA receptors | ||||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 | |||
| REF 2 | ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.